Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool for Alzheimer's Disease Diagnostics

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 1007-1020

  Zhang, William I ^a,b   Antonios, Gregory ^a   Rabano, Alberto ^c   Bayer, Thomas A ^a   Schneider, Anja ^a,b,d   Rizzoli, Silvio O ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB)   (Germany)

^c Instituto de Salud Carlos III   (Spain)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; amyloid ; diagnostics; imaging; super resolution; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[4-38]; TAU PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; ARTICLE; CAMERA; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPUTER PROGRAM; CONFOCAL MICROSCOPE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIODE LASER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIFLUORESCENCE MICROSCOPE; HUMAN; IN VITRO STUDY; MICROSCOPE; MICROSCOPY; MILD COGNITIVE IMPAIRMENT; MOLECULAR WEIGHT; NEUROIMAGING; NEUROLOGICAL DIAGNOSTIC DEVICE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN STRUCTURE; SENSITIVITY AND SPECIFICITY; STIMULATED EMISSION DEPLETION MICROSCOPE; STIMULATED EMISSION DEPLETION MICROSCOPY; CEREBROSPINAL FLUID; FEMALE; IMAGE PROCESSING; MALE; MENTAL HEALTH;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MENTAL STATUS SCHEDULE; MICROSCOPY, CONFOCAL; MILD COGNITIVE IMPAIRMENT; PROTEIN AGGREGATES; TAU PROTEINS;

EID: 84937036112     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150064     Document Type: Article

References (41)

1. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34, 185-204.
2. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70, 410-426.
3. Shaw LM, Korecka M, Clark CM, Lee VM-Y, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6, 295-303.
4. Aluise CD, Sowell RA, Butterfield DA (2008) Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta 1782, 549-558.
5. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
6. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
7. Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM (2013) Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol 9, 371-381.
8. Zetterberg H, Blennow K (2013) Cerebrospinal fluid biomarkers for Alzheimer's disease: More to come? J Alzheimers Dis 33 Suppl 1, S361-S369.
9. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38, 643-648.
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
11. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562.
12. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24, 2716-2726.
13. Georganopoulou DG, Chang L, Nam J-M, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102, 2273-2276.
14. Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G (2012) The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis 31, 865-878.
15. Ringman JM, Tomic JL, Coppola G, Elashoff D, Gylys KH, Glabe CG (2012) Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers. Dement Geriatr Cogn Dis Extra 2, 652-657.
16. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8, e67898.
17. Wang-Dietrich L, Funke SA, Kühbach K, Wang K, Besmehn A, Willbold S, Cinar Y, Bannach O, Birkmann E, Willbold D (2013) The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 34, 985-994.
18. Bruggink KA, Jongbloed W, Biemans EALM, Veerhuis R, Claassen JAHR, Kuiperij HB, Verbeek MM (2013) Amyloid- β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem 433, 112-120.
19. Höltta¨ M, Hansson O, Andreasson U, Hertze J, Minthon L, Na¨gga K, Andreasen N, Zetterberg H, Blennow K (2013) Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One 8, e66381.
20. Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash- Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A (2014) A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci 34, 2884-2897.
21. Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C (2014) Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep 7, 261-268.
22. Hell SW (2007) Far-field optical nanoscopy. Science 316, 1153-1158.
23. Hell SW, Wichmann J (1994) Breaking the diffraction resolution limit by stimulated emission: Stimulated-emission-depletion fluorescence microscopy. Opt Lett 19, 780-782.
24. Willig KI, Rizzoli SO, Westphal V, Jahn R, Hell SW (2006) STED microscopy reveals that synaptotagmin remains clustered after synaptic vesicle exocytosis. Nature 440, 935-939.
25. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, Nordberg A, Ba¨ckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
26. Martínez-Martín P, Avila J (2010) Alzheimer Center Reina Sofia Foundation: Fighting the disease and providing overall solutions. J Alzheimers Dis 21, 337-348.
27. Pa¨iviö a, Jarvet J, Gra¨slund A, Lannfelt L, Westlind- Danielsson A (2004) Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: Conceivable neuropathogen in arctic mutant carriers. J Mol Biol 339, 145-159.
28. Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA (2013) N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol 126, 189-205.
29. Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2, 121-130.
30. Rosén C, Hansson O, Blennow K, Zetterberg H (2013) Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener 8, 20.
31. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
32. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A (1988) Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 24, 641-652.
33. Ehrensperger MM, Berres M, Taylor KI, Monsch AU (2010) Early detection of Alzheimer's disease with a total score of the German CERAD. J Int Neuropsychol Soc 16, 910-920.
34. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL (2013) Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73, 104-119.
35. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ (2013) New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement 9, 99-112.
36. Santos AN, Ewers M, Minthon L, Simm A, Silber R-E, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29, 171-176.
37. Funke SA, Wang L, Birkmann E, Willbold D (2010) Single-particle detection system for Abeta aggregates: Adaptation of surface-fluorescence intensity distribution analysis to laser scanning microscopy. Rejuvenation Res 13, 206-209.
38. Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127, 2264-2271.
39. Funke SA (2011) Detection of soluble amyloid-β oligomers and insoluble high-molecular-weight particles in CSF: Development of methods with potential for diagnosis and therapy monitoring of Alzheimer's disease. Int J Alzheimers Dis 2011, 151645.
40. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
41. Schermelleh L, Heintzmann R, Leonhardt H (2010) A guide to super-resolution fluorescence microscopy. J Cell Biol 190, 165-175.